Mark Laubach is professor of neuroscience at American University. His research group focuses on understanding the prefrontal cortex and its role in learning and decision making. Laubach and his graduate students, working with Alexxai Kravitz, maintain the National Science Foundation-supported OpenBehavior project.

Mark Laubach
Professor of neuroscience
American University
From this contributor
Unleashing the power of DIY innovation in behavioral neuroscience
Widespread adoption of open-source tools calls for more support and training.
Unleashing the power of DIY innovation in behavioral neuroscience
Explore more from The Transmitter
Exclusive: The 23 studies the FDA based its expanded leucovorin label on
The studies include 46 people, mostly toddlers, who have cerebral folate deficiency due to variants in a folate transporter.

Exclusive: The 23 studies the FDA based its expanded leucovorin label on
The studies include 46 people, mostly toddlers, who have cerebral folate deficiency due to variants in a folate transporter.
Autism researchers ‘pleasantly surprised’ by list of NIH data project grantees, despite initial concerns
An atypical funding mechanism, truncated application timeline and opaque review process had generated concern over the quality of projects that would be selected for the Autism Data Science Initiative.

Autism researchers ‘pleasantly surprised’ by list of NIH data project grantees, despite initial concerns
An atypical funding mechanism, truncated application timeline and opaque review process had generated concern over the quality of projects that would be selected for the Autism Data Science Initiative.
Exclusive: Who is Richard Frye, the neurologist who researches and advocates for leucovorin as an autism treatment?
Frye has led two placebo-controlled trials of the folate supplement in autistic people; the first was suspended by regulators, and the other has yet to be published.

Exclusive: Who is Richard Frye, the neurologist who researches and advocates for leucovorin as an autism treatment?
Frye has led two placebo-controlled trials of the folate supplement in autistic people; the first was suspended by regulators, and the other has yet to be published.